Research| Case et al. report that low-dose interleukin-2 clonally expands Tregs and maintains their suppressive program by bypassing BACH2 downregulation in patients with acute coronary syndrome from the LILACS trial.
@aydencase.bsky.social
rdcu.be/ephaW